Please assess the completion status of the following clinical trial:

Trial Title: IC14 Antibodies to Treat Individuals With Acute Lung Injury

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Presence of ALI, defined as the following:~  1. Acute onset (less than 28 days from study entry)~ 2. PaO2/FiO2 of less than 300~ 3. Bilateral infiltrates consistent with pulmonary edema on frontal chest radiograph (infiltrates may be patchy, diffuse, homogeneous, or asymmetric)~ 4. Requirement for positive pressure ventilation via endotracheal tube~ 5. No clinical evidence of left atrial hypertension~* Clinical indication for antimicrobial therapy at the time of randomization~* Anticipated duration of mechanical ventilation greater than 48 hours~Exclusion Criteria:~* Treatment with a drug or device within 30 days prior to study entry that has not received regulatory approval at the time of study entry~* Does not meet safety criteria for bronchoscopic alveolar lavage either at baseline or is anticipated to be too high a risk for lavage on Day 1 of the study~* Intubation for cardiopulmonary arrest~* Intubation for status asthmaticus, pulmonary embolus, or myocardia infarction~* Anticipated survival less than 48 hours from intubation~* Anticipated survival less than 28 days due to pre-existing medical condition

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).